Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lanadelumab Treatment Outcomes in HAE Polish Patients Treated in the Scope of National Drug Program (NDP). Prospective, Multicenter Observational Study

NCT05147181 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05147181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05147181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lanadelumab Treatment Outcomes in HAE Polish Patients Treated in the Scope of National Drug Program (NDP). Prospective, Multicenter Observational Study
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
March 11, 2022
Completion date
November 13, 2025
Enrollment
48 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)